Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors

被引：22

作者：

Chen, Yu-Mu ^{[1
]}

Lai, Chien-Hao ^{[1
]}

Rau, Kun-Ming ^{[2
,3
]}

Huang, Cheng-Hua ^{[2
,3
]}

Chang, Huang-Chih ^{[1
]}

Chao, Tung-Ying ^{[1
]}

Tseng, Chia-Cheng ^{[1
]}

Fang, Wen-Feng ^{[1
,4
]}

Chung, Yu-Hsiu ^{[1
]}

Wang, Yi-Hsi ^{[1
]}

Su, Mao-Chang ^{[1
]}

Huang, Kuo-Tung ^{[1
]}

Liu, Shih-Feng ^{[1
]}

Chen, Hung-Chen ^{[1
]}

Chang, Ya-Chun ^{[1
]}

Chang, Yu-Ping ^{[1
]}

Wang, Chin-Chou ^{[1
]}

Lin, Meng-Chih ^{[1
]}

机构：

[1] Chang Gung Univ, Chang Gung Mem Hosp, Div Pulm & Crit Care Med, Dept Internal Med,Kaohsiung Med Ctr,Coll Med, 123 Ta Pei Rd, Kaohsiung, Taiwan

[2] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hematol Oncol, Kaohsiung, Taiwan

[3] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan

[4] Chang Gung Univ Sci & Technol, Dept Resp Care, Chiayi Campus, Chiayi, Taiwan

来源：

BMC CANCER | 2016年 / 16卷

关键词：

Neutrophil-to-lymphocyte ratio; Lymphocyte-to-monocyte ratio; Readministration; Non-small cell lung cancer; Epidermal growth factor receptor; Tyrosine kinase inhibitor; PLATINUM-BASED CHEMOTHERAPY; TO-LYMPHOCYTE RATIO; PROGNOSTIC-SIGNIFICANCE; 1ST-LINE TREATMENT; MONOCYTE RATIO; BREAST-CANCER; OPEN-LABEL; PHASE-III; NEUTROPHIL; GEFITINIB;

D O I：

10.1186/s12885-016-2917-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) readministration to lung cancer patients is common owing to the few options available. Impact of clinical factors on prognosis of EGFR-mutant non-small cell lung cancer (NSCLC) patients receiving EGFR-TKI readministration after first-line EGFR-TKI failure and a period of TKI holiday remains unclear. Through this retrospective study, we aimed to understand the impact of clinical factors in such patients. Methods: Of 1386 cases diagnosed between December 2010 and December 2013, 80 EGFR-mutant NSCLC patients who were readministered TKIs after failure of first-line TKIs and intercalated with at least one cycle of cytotoxic agent were included. We evaluated clinical factors that may influence prognosis of TKI readministration as well as systemic inflammatory status in terms of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR). Baseline NLR and LMR were estimated at the beginning of TKI readministration and trends of NLR and LMR were change amount from patients receiving first-Line TKIs to TKIs readministration. Results: Median survival time since TKI readministration was 7.0 months. In the univariable analysis, progression free survival (PFS) of first-line TKIs, baseline NLR and LMR, and trend of LMR were prognostic factors in patients receiving TKIs readministration. In the multivariate analysis, only PFS of first-line TKIs (p < 0.001), baseline NLR (p = 0.037), and trend of LMR (p = 0.004) were prognostic factors. Conclusion: Longer PFS of first-line TKIs, low baseline NLR, and high trend of LMR were good prognostic factors in EGFR-mutant NSCLC patients receiving TKI readministration.

引用

页数：7

共 29 条

[11] Does T790M Disappear? Successful Gefitinib Rechallenge After T790M Disappearance in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer [J].